ADC

17개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved17 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCCurated CoreFDAstaleGenmabApproved

Tisotumab Vedotin (Tisotumab Vedotin)

Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung · Solid Malignancies

#SolidMalignancies#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 14Status Approved
ADCLimited DatastaleBristol-Myers SquibbPhase 2

Luspatercept (Luspatercept)

Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 51Status Recruiting
ADCLimited DatastaleCSPC ZhongQi Pharmaceutical Tec…Phase 1

an antibody drug conjugate (an antibody drug conjugate)

Neoplasms · Neoplasms

#Neoplasms#ADC#Phase1#antibody-drug-conjugate#CSPC
Trials 31Status Active
ADCLimited DatastaleRochePhase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 and Pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 30Status Recruiting
ADCCurated CorestaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Breast Neoplasms; Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#BioJungboMoa-pick#antibody-drug-conjugate+3
Trials 29Status Recruiting
ADCLimited DatastaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#antibody-drug-conjugate#NeoplasmMetastasis+1
Trials 24Status Recruiting
ADCLimited DatastaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)

Uterine Cervical Neoplasms · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#ADC#Preclinical#antibody-drug-conjugate#RemeGen
Trials 13Status Recruiting
ADCLimited DatastaleAstraZenecaPhase 2

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 11Status Recruiting
ADCLimited DatastaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin-Blmf)

Multiple Myeloma; Neoplasms · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#Neoplasms+1
Trials 9Status Recruiting
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin (glembatumumab vedotin)

Advanced Malignant Solid Neoplasm; Estrogen Receptor Negative · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#AdvancedMalignantSolidNeoplasm+2
Trials 9Status Active
ADCLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

[vic-]trastuzumab duocarmazine (SYD985, SYD985 ([vic-]trastuzumab duocarmazine))

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 7Status Recruiting
ADCLimited DatastaleAstraZenecaPhase 3

Sonesitatug vedotin (Sonesitatug vedotin)

Stomach Neoplasms · Gastric Cancer

#GastricCancer#ADC#Phase3#antibody-drug-conjugate#StomachNeoplasms+2
Trials 6Status Recruiting
ADCLimited DatastaleSeagen Inc.Phase 2

cBR96-Doxorubicin Immunoconjugate (SGN-15, SGN-15 (cBR96-Doxorubicin Immunoconjugate))

Prostatic Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase2#antibody-drug-conjugate#ProstaticNeoplasms+1
Trials 5Status Active
ADCLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Patritumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 4Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

Patritumab (Patritumab)

Head and Neck Neoplasms · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#ADC#Phase2#antibody-drug-conjugate#HeadandNeckNeoplasms+1
Trials 2Status Active
ADCLimited DatastaleSeagen, a wholly owned subsidia…Phase 1

Felmetatug Vedotin (Felmetatug Vedotin)

Ovarian Neoplasms; Peritoneal Neoplasms · HER2

#HER2#ADC#Phase1#antibody-drug-conjugate#OvarianNeoplasms+2
Trials 1Status Discontinued
ADCLimited DatastaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+1
Trials 1Status Recruiting